NovoCure Limited (NASDAQ:NVCR) insider Yoram Palti sold 30,000 shares of NovoCure Limited stock in a transaction on Monday, November 13th. The stock was sold at an average price of $17.13, for a total transaction of $513,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Yoram Palti also recently made the following trade(s):
- On Thursday, November 9th, Yoram Palti sold 30,000 shares of NovoCure Limited stock. The stock was sold at an average price of $18.25, for a total transaction of $547,500.00.
- On Tuesday, November 7th, Yoram Palti sold 60,000 shares of NovoCure Limited stock. The stock was sold at an average price of $21.06, for a total transaction of $1,263,600.00.
- On Thursday, November 2nd, Yoram Palti sold 30,000 shares of NovoCure Limited stock. The stock was sold at an average price of $21.78, for a total transaction of $653,400.00.
Shares of NovoCure Limited (NVCR) opened at $18.60 on Friday. The company has a current ratio of 5.90, a quick ratio of 5.30 and a debt-to-equity ratio of 0.83. NovoCure Limited has a 1-year low of $6.00 and a 1-year high of $22.30.
NovoCure Limited (NASDAQ:NVCR) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.07. The firm had revenue of $50.10 million for the quarter, compared to analyst estimates of $43.45 million. NovoCure Limited had a negative net margin of 47.45% and a negative return on equity of 57.68%. The business’s quarterly revenue was up 130.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.39) earnings per share. analysts expect that NovoCure Limited will post -0.63 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Insider Selling: NovoCure Limited (NVCR) Insider Sells $513,900.00 in Stock” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2017/11/17/insider-selling-novocure-limited-nvcr-insider-sells-513900-00-in-stock.html.
Large investors have recently bought and sold shares of the business. Bank of Montreal Can boosted its holdings in NovoCure Limited by 1,919.7% in the second quarter. Bank of Montreal Can now owns 7,069 shares of the medical equipment provider’s stock valued at $122,000 after purchasing an additional 6,719 shares during the last quarter. BNP Paribas Arbitrage SA boosted its holdings in NovoCure Limited by 792.5% in the second quarter. BNP Paribas Arbitrage SA now owns 7,229 shares of the medical equipment provider’s stock valued at $125,000 after purchasing an additional 6,419 shares during the last quarter. Nisa Investment Advisors LLC purchased a new stake in NovoCure Limited in the second quarter valued at $126,000. Trexquant Investment LP purchased a new stake in NovoCure Limited in the third quarter valued at $212,000. Finally, Fox Run Management L.L.C. purchased a new stake in NovoCure Limited in the second quarter valued at $225,000. 36.21% of the stock is currently owned by institutional investors.
Several equities analysts have issued reports on NVCR shares. Zacks Investment Research raised shares of NovoCure Limited from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a report on Tuesday, October 31st. Mizuho assumed coverage on shares of NovoCure Limited in a report on Wednesday, September 6th. They set a “buy” rating and a $25.00 price objective on the stock. Wedbush reissued an “outperform” rating and set a $25.00 price objective (down from $29.00) on shares of NovoCure Limited in a report on Friday, October 27th. Finally, BidaskClub raised shares of NovoCure Limited from a “buy” rating to a “strong-buy” rating in a report on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. NovoCure Limited has an average rating of “Buy” and a consensus target price of $21.00.
About NovoCure Limited
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.